Ed is a partner in our Corporate team and dual-qualified in England and Wales and California. He advises clients on strategic buy and sell-side M&A transactions, venture capital and growth equity financings, joint ventures, and restructurings, particularly within the technology and life sciences sectors.
Ed has extensive experience structuring, negotiating, and executing complex domestic and cross-border matters, regularly working across the UK, Europe, Nordics, and North America.
Ed is noted as a 'Key Lawyer' for mid-market M&A deals by Legal 500 UK 2025 and praised by clients for providing "the most exceptional service … always [going] above and beyond".
We have advised a syndicate of leading global life sciences investors including Access Biotechnology, Canaan Partners and SR One on their landmark US$140 million series A investment in Draig Therapeutics.
Press release
par Ed Chapman et Jack Coventry
Advising on Draig Therapeutics' US$140 million series A financing
par plusieurs auteurs
Advising Grant Thornton UAE on its business combination with Grant Thornton Advisors LLC
par plusieurs auteurs
par Vanessa Komm
par Dr. Michael Kieffer et Vanessa Komm
par Emma Tait et Lorraine Smith
par plusieurs auteurs
par Oz Watson et Giles Crown
par Dr. Paul Voigt, Lic. en Derecho, CIPP/E et Stephanie Richter, LL.M. (Torino), CIPP/E
par plusieurs auteurs
par Sasun Sepoyan et Otto Sleeking